HLS Net Income From Continuing Ops from 2010 to 2026
| HLS Stock | CAD 4.48 0.17 3.66% |
Net Loss | First Reported 2018-06-30 | Previous Quarter -2.7 M | Current Value -3.9 M | Quarterly Volatility 4 M |
Check HLS Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among HLS Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 13.2 M, Interest Expense of 12.2 M or Total Revenue of 55.7 M, as well as many indicators such as Price To Sales Ratio of 1.19, Dividend Yield of 0.0102 or PTB Ratio of 0.73. HLS financial statements analysis is a perfect complement when working with HLS Therapeutics Valuation or Volatility modules.
HLS | Net Income From Continuing Ops |
Evaluating HLS Therapeutics's Net Income From Continuing Ops across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into HLS Therapeutics's fundamental strength.
Latest HLS Therapeutics' Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of HLS Therapeutics over the last few years. It is HLS Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in HLS Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
HLS Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (14,391,377) | |
| Coefficient Of Variation | (50.29) | |
| Mean Deviation | 6,071,230 | |
| Median | (13,117,000) | |
| Standard Deviation | 7,237,709 | |
| Sample Variance | 52.4T | |
| Range | 26.7M | |
| R-Value | (0.66) | |
| Mean Square Error | 31.5T | |
| R-Squared | 0.44 | |
| Significance | 0 | |
| Slope | (946,224) | |
| Total Sum of Squares | 838.2T |
HLS Net Income From Continuing Ops History
About HLS Therapeutics Financial Statements
HLS Therapeutics investors utilize fundamental indicators, such as Net Income From Continuing Ops, to predict how HLS Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Loss | -17.7 M | -18.6 M |
Other Information on Investing in HLS Stock
HLS Therapeutics financial ratios help investors to determine whether HLS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HLS with respect to the benefits of owning HLS Therapeutics security.